Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL

Sei Investments Co. increased its stake in Personalis, Inc. (NASDAQ:PSNL) by 148.3% in the 1st quarter, Holdings Channel reports. The fund owned 139,046 shares of the company’s stock after buying an additional 83,040 shares during the quarter. Sei Investments Co.’s holdings in Personalis were worth $886,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PSNL. Dimensional Fund Advisors LP raised its position in Personalis by 8.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares in the last quarter. AlphaCentric Advisors LLC boosted its holdings in shares of Personalis by 34.0% in the 1st quarter. AlphaCentric Advisors LLC now owns 64,032 shares of the company’s stock worth $408,000 after purchasing an additional 16,236 shares in the last quarter. Swiss National Bank purchased a new position in shares of Personalis in the 1st quarter worth about $671,000. Janney Montgomery Scott LLC increased its position in shares of Personalis by 150.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 75,000 shares of the company’s stock valued at $478,000 after purchasing an additional 45,000 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Trading Up 1.5%

Shares of NASDAQ:PSNL opened at $14.42 on Friday. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -13.23 and a beta of 2.27. The company has a 50-day moving average price of $12.62 and a 200-day moving average price of $9.45. Personalis, Inc. has a 12 month low of $4.44 and a 12 month high of $16.39.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million for the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. As a group, research analysts forecast that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insider Activity at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the sale, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,783,662. This represents a 2.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 435,032 shares of company stock valued at $5,599,929. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PSNL shares. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. BTIG Research increased their price target on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Finally, Morgan Stanley upped their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.25.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.